Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.47 |
| ▸ | HTT | P42858 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 6/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | PLG | P00747 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | GALR3 | O60755 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9898944 | 1.00 | ALDH1A1 (0.47) | ALDH1A1HTTGAAL3MBTL1THRB | |
| SCHEMBL9898940 | 1.00 | ALDH1A1 (0.47) | ALDH1A1HTTGAAL3MBTL1THRB | |
| SCHEMBL12350182 | 0.89 | ALDH1A1 (0.47) | ALDH1A1HTTGAAL3MBTL1THRB | |
| SCHEMBL12350206 | 0.86 | ALDH1A1 (0.43) | ALDH1A1HTTGAAL3MBTL1THRB | |
| SCHEMBL287615 | 0.86 | ALDH1A1 (0.47) | ALDH1A1HTTGAAL3MBTL1THRB | |
| SCHEMBL12350209 | 0.86 | ALDH1A1 (0.44) | ALDH1A1HTTGAAL3MBTL1THRB | |
| SCHEMBL287614 | 0.86 | ALDH1A1 (0.47) | ALDH1A1HTTGAAL3MBTL1THRB | |
| SCHEMBL1440527 | 0.84 | ALDH1A1 (0.48) | ALDH1A1HTTGAAL3MBTL1THRB | |
| SCHEMBL1440524 | 0.84 | ALDH1A1 (0.48) | ALDH1A1HTTGAAL3MBTL1THRB | |
| SCHEMBL20894943 | 0.84 | LMNA (0.47) | ALDH1A1HTTGAAL3MBTL1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895548-B2 | Pharmaceutical composition for treating alzheimer's disease | SHIONOGI & CO., LTD. (JP) | 2014-11-25 | — | — | US | disclosed |
| US-8895548-B2 | Pharmaceutical composition for treating alzheimer's disease | SHIONOGI & CO., LTD. (JP) | 2014-11-25 | — | — | US | disclosed |
| US-8884062-B2 | Aminodihydrothiazine derivatives substituted with a cyclic group | SHIONOGI & CO., LTD. (JP) | 2014-11-11 | — | — | US | disclosed |
| US-8884062-B2 | Aminodihydrothiazine derivatives substituted with a cyclic group | SHIONOGI & CO., LTD. (JP) | 2014-11-11 | — | — | US | disclosed |
| US-20140073815-A1 | AMINODIHYDROTHIAZINE DERIVATIVES SUBSTITUTED WITH A CYCLIC GROUP | SHIONOGI & CO., LTD. (JP) | 2014-03-13 | — | — | US | disclosed |
| US-20140073815-A1 | AMINODIHYDROTHIAZINE DERIVATIVES SUBSTITUTED WITH A CYCLIC GROUP | SHIONOGI & CO., LTD. (JP) | 2014-03-13 | — | — | US | disclosed |
| US-20140058097-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING ALZHEIMER'S DISEASE | SHIONOGI & CO., LTD. (JP) | 2014-02-27 | — | — | US | disclosed |
| US-20140058097-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING ALZHEIMER'S DISEASE | SHIONOGI & CO., LTD. (JP) | 2014-02-27 | — | — | US | disclosed |
| US-8653067-B2 | Pharmaceutical composition for treating Alzheimer's disease | SHIONOGI & CO., LTD. (JP) | 2014-02-18 | — | — | US | disclosed |
| US-8653067-B2 | Pharmaceutical composition for treating Alzheimer's disease | SHIONOGI & CO., LTD. (JP) | 2014-02-18 | — | — | US | disclosed |
| US-8541408-B2 | Aminodihydrothiazine derivatives substituted with a cyclic group | SHIONOGI & CO., LTD. (JP) | 2013-09-24 | — | — | US | disclosed |
| US-8507479-B2 | — | — | 2013-08-13 | — | — | US | disclosed |
| US-8507479-B2 | — | — | 2013-08-13 | — | — | US | disclosed |
| US-20120172355-A1 | AMINODIHYDROTHIAZINE DERIVATIVES SUBSTITUTED WITH A CYCLIC GROUP | SHIONOGI & CO., LTD. (JP) | 2012-07-05 | — | — | US | disclosed |
| US-8168630-B2 | Aminodihydrothiazine derivatives substituted with a cyclic group | SHIONOGI & CO., LTD. (JP) | 2012-05-01 | — | — | US | disclosed |
| US-20100160290-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING ALZHEIMER'S DISEASE | SHIONOGI & CO., LTD. (JP) | 2010-06-24 | — | — | US | disclosed |
| US-20100075957-A1 | AMINODIHYDROTHIAZINE DERIVATIVES SUBSTITUTED WITH A CYCLIC GROUP | SHIONOGI & CO., LTD. (JP) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160290-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING ALZHEIMER'S DISEASE | NR1H2, NR1H3, NR0B1 | ALDH1A1 2485/4885HTT 78/4885GAA 2383/4885 |
| US-20120172355-A1 | AMINODIHYDROTHIAZINE DERIVATIVES SUBSTITUTED WITH A CYCLIC GROUP | APP, IAPP, APBA1 | ALDH1A1 1525/4885HTT 4/4885GAA 3572/4885 |
| US-20140058097-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING ALZHEIMER'S DISEASE | NR1H2, NR1H3, NR0B1 | ALDH1A1 2665/4885HTT 79/4885GAA 2550/4885 |
| US-20100075957-A1 | AMINODIHYDROTHIAZINE DERIVATIVES SUBSTITUTED WITH A CYCLIC GROUP | APP, IAPP, APBA1 | ALDH1A1 1383/4885HTT 6/4885GAA 3449/4885 |
| US-20140073815-A1 | AMINODIHYDROTHIAZINE DERIVATIVES SUBSTITUTED WITH A CYCLIC GROUP | APP, IAPP, APBA1 | ALDH1A1 1525/4885HTT 4/4885GAA 3572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.